Clinical Trial Detail

NCT ID NCT03829410
Title Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Trovagene, Inc.
Indications

colon cancer

rectum cancer

Therapies

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib

Age Groups: adult senior

No variant requirements are available.